{
  "source": "PA-Notification-Arcalyst.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1009-13\nProgram Prior Authorization/Notification\nMedication Arcalyst® (rilonacept)\nP&T Approval Date 7/2011, 7/2012, 7/2013, 8/2013, 7/2014, 2/2015, 4/2016, 4/2017, 4/2018,\n4/2019, 4/2020, 5/2021, 5/2022, 5/2023, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nArcalyst (rilonacept) is an interleukin-1 blocker indicated for the treatment of Cryopyrin-\nAssociated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome\n(FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older. Arcalyst is\nalso indicated for the maintenance of remission of Deficiency of Interleukin-1 Receptor\nAntagonist (DIRA) in adults and pediatric patients weighing at least 10 kg. Additionally, Arcalyst\nis indicated for the treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in\nadult and children 12 years and older.1\n2. Coverage Criteriaa:\nA. Cryopyrin-Associated Periodic Syndromes (CAPS)\n1. Initial Authorization\na. Arcalyst will be approved based on the following criterion:\n(1) Diagnosis of Cryopyrin-Associated Periodic Syndromes (CAPS), including\nFamilial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome\n(MWS)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Arcalyst will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Arcalyst therapy\nAuthorization will be issued for 12 months.\nB. Deficiency of Interleukin-1 Receptor Antagonist (DIRA)\n1. Initial Authorization\na. Arcalyst will be approved based on the following criteria:\n(1) Diagnosis of Deficiency of Interleukin-1 Receptor Antagonist (DIRA)\n© 2025 UnitedHealthcare Services, Inc.\n1\n-AND–\n(2) Disease is in remission (e.g., diary score of < 0.5 [reflecting no fever, skin rash\nand bone pain], acute phase reactants [<0.5 mg/dL CRP], absence of objective\nskin rash, no radiological evidence of active bone lesions)\nAuthorization will ",
    "re of < 0.5 [reflecting no fever, skin rash\nand bone pain], acute phase reactants [<0.5 mg/dL CRP], absence of objective\nskin rash, no radiological evidence of active bone lesions)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Arcalyst will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Arcalyst therapy\nAuthorization will be issued for 12 months.\nC. Pericarditis\n1. Initial Authorization\na. Arcalyst will be approved based on the following criterion:\n(1) Diagnosis of recurrent pericarditis (RP)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Arcalyst will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Arcalyst therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class\n• Supply limits may be in place.\n4. References:\n1. Arcalyst [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; May 2021.\n© 2025 UnitedHealthcare Services, Inc.\n2\nProgram Prior Authorization/Notification - Arcalyst (rilonacept)\nChange Control\n7/2013 Annual review. Updated formatting. Add IL-1 agents as a requirement to\ncriteria. Removed age 12 from coverage criteria and added\nreauthorization criteria.\n8/2013 Removed IL-1 and added ‘clinical symptoms’ and ‘elevated acute phase\nreactants.’\n7/2014 Annual review with no change to coverage criteria.\n2/2015 Annual review with no change to coverage criteria. Updated background\nand references.\n4/2016 Annual",
    "d ‘elevated acute phase\nreactants.’\n7/2014 Annual review with no change to coverage criteria.\n2/2015 Annual review with no change to coverage criteria. Updated background\nand references.\n4/2016 Annual review. Revised criteria to only require diagnosis. Updated\nbackground and references.\n4/2017 Annual review with no change to coverage criteria. Updated references.\n4/2018 Annual review with no change to coverage criteria.\n4/2019 Annual review with no change to coverage criteria.\n4/2020 Annual review with no change to coverage criteria.\n5/2021 Annual review. Added coverage criteria for deficiency of IL-1 receptor\nantagonist and recurrent pericarditis. Updated background and references.\n5/2022 Annual review. Updated references.\n5/2023 Annual review with no changes to coverage criteria. Added state mandate\nfootnote and updated reference format.\n5/2024 Annual review with no change to coverage criteria.\n5/2025 Annual review with no change to coverage criteria.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}